New discovery could help protect the liver from fructose-induced diseases

NewsGuard 100/100 Score

A team of international researchers including Monash University academics has discovered that, contrary to previous belief, fructose causes liver toxicity by changing the barrier function of the intestine.

This new discovery not only deepens our understanding of how fructose affects the liver, it could also protect it from numerous life-threatening diseases.

The new study, published today (August 25th) in Nature Metabolism, shows that fructose affects the liver only after it causes intestinal barrier disruption, therefore treatments that prevent barrier disruption could protect the liver from fructose-induced diseases including non-alcoholic fatty liver disease (NAFLD), fibrosis and cancer.

Fructose is a simple sugar which can be found in high quantities in soft drinks, sauces and fast foods. With the advent of modern biochemistry and metabolic analysis, in recent times scientists have discovered that fructose is up to three times more potent than glucose in increasing liver fat.

Excessive fructose consumption has been linked to the recent surge in NAFLD - one of the most common metabolic disorders - and its associated co-morbidities, which include liver failure, cirrhosis, and cancer.

Leading Australian metabolic disease expert, Professor Mark Febbraio from Monash’s Institute of Pharmaceutical Sciences, was part of the international team of researchers led by Professor Michael Karin from The University of California San Diego, School of Medicine.

The findings from this study make it clear that fructose does its damage in the intestine and if intestinal barrier deterioration is prevented, the fructose does little harm to the liver.”

Professor Febbraio, Leading Australian metabolic disease expert, Monash’s Institute of Pharmaceutical Sciences

The intestine is an organ that makes up part of the gastrointestinal system (more commonly known as the gut). In recent years it’s become evident that excessive fructose metabolism in the gut reduces the production of proteins that maintain the gut barrier, which can lead to a chronic inflammation condition called endotoxemia, as documented in animal studies and pediatric NAFLD patients.

The international team of researchers found that by adding a cell signalling protein called ‘tumor necrosis factor’ (TNF) to hepatocytes stimulates the metabolism of fructose and increases the production of the enzymes that convert the molecule ‘acetyl CoA’ to fatty acids.

A large increase in the expression of these enzymes was also detected in livers of fructose-fed mice. Conversely, genetic modification that reduced TNF production was found to protect mice from fructose-provoked NAFLD, which is a very exciting step forward for the treatment of diseases which can evolve from this all too common liver disorder.”

Professor Febbraio

Although education and increased awareness are the best solutions to the problem of fructose-induce liver disease, for those individuals who progress to the severe form of NAFLD, known as non-alcoholic steatohepatitis (NASH), the findings described in this study offer some hope of a future therapy based on gut barrier restoration.

This study clearly demonstrates that maintaining gut barrier integrity is a therapeutic target to treat liver disease associated with high fructose consumption.

The researchers will now focus on screening drug candidates that target key proteins in the maintenance of gut barrier integrity.

The full study can be found at: https://www.nature.com/articles/s42255-020-0261-2

Source:
Journal reference:

Todoric, J., et al (2020) Fructose stimulated de novo lipogenesis is promoted by inflammation. Nature Metabolism. doi.org/10.1038/s42255-020-0261-2.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show